Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100
- PMID: 11973635
- DOI: 10.1038/sj.gt.3301694
Lymphotactin cotransfection enhances the therapeutic efficacy of dendritic cells genetically modified with melanoma antigen gp100
Abstract
Lymphotactin (Lptn) is a C chemokine that attracts T cells and NK cells. Dendritic cells (DC) are highly efficient, specialized antigen-presenting cells and antigen-pulsed DC has been regarded as promising vaccines in cancer immunotherapy. The aim of our present study is to improve the therapeutic efficacy of DC-based tumor vaccine by increasing the preferential chemotaxis of DC to T cells. In this study, Lptn and/or melanoma-associated antigen gp100 were transfected into mouse bone marrow-derived DC, which were used as vaccines in B16 melanoma model. Immunization of C57BL/6 mice with DC adenovirally cotransfected with Lptn and gp100 (Lptn/gp100-DC) could enhance the cytotoxicities of CTL and NK cells, increase the production of IL-2 and interferon-gamma significantly, as compared with immunization with gp100-DC, Lptn-DC, LacZ-DC, DC or PBS counterparts. The Lptn/gp100-DC immunized mice exhibited resistance to tumor challenge most effectively. It was found that the tumor mass of mice vaccinated by Lptn/gp100-DC showed obvious necrosis and inflammatory cell infiltration. In vivo depletion analysis demonstrated that CD8(+) T cells are the predominant T cell subset responsible for the antitumor effect of Lptn/gp100-DC and CD4(+) T cells were necessary in the induction phase of tumor rejection, while NK cells were less important although they participated in the antitumor response either in the induction phase or in the effector phase. In the murine model with the pre-established subcutaneous B16 melanoma, immunization with Lptn/gp100-DC inhibited the tumor growth most significantly when compared with other counterparts. These findings provide a potential strategy to improve the efficacy of DC-based tumor vaccines.
Similar articles
-
Lymphotactin gene-modified bone marrow dendritic cells act as more potent adjuvants for peptide delivery to induce specific antitumor immunity.J Immunol. 1998 Dec 1;161(11):6238-44. J Immunol. 1998. PMID: 9834111
-
[Enhanced antitumor effects induced by lymphotactin gene-modified dendritic cells after pulsed with tumor antigen peptide].Zhonghua Yi Xue Za Zhi. 1999 Mar;79(3):170-3. Zhonghua Yi Xue Za Zhi. 1999. PMID: 11601032 Chinese.
-
Enhanced therapeutic efficacy of tumor RNA-pulsed dendritic cells after genetic modification with lymphotactin.Hum Gene Ther. 1999 May 1;10(7):1151-61. doi: 10.1089/10430349950018148. Hum Gene Ther. 1999. PMID: 10340547
-
Interleukin-2: developing additional cytokine gene therapies using fibroblasts or dendritic cells to enhance tumor immunity.Cancer J Sci Am. 2000 Feb;6 Suppl 1:S61-6. Cancer J Sci Am. 2000. PMID: 10685662 Review.
-
Adenovirus-enhanced receptor-mediated transferrinfection for the generation of tumor vaccines.Cytokines Mol Ther. 1996 Sep;2(3):185-91. Cytokines Mol Ther. 1996. PMID: 9384703 Review.
Cited by
-
Transfection of colorectal cancer cells with chemokine MCP-3 (monocyte chemotactic protein-3) gene retards tumor growth and inhibits tumor metastasis.World J Gastroenterol. 2002 Dec;8(6):1067-72. doi: 10.3748/wjg.v8.i6.1067. World J Gastroenterol. 2002. PMID: 12439927 Free PMC article.
-
Structure-function guided modeling of chemokine-GPCR specificity for the chemokine XCL1 and its receptor XCR1.Sci Signal. 2019 Sep 3;12(597):eaat4128. doi: 10.1126/scisignal.aat4128. Sci Signal. 2019. PMID: 31481523 Free PMC article.
-
Chemokines as Cancer Vaccine Adjuvants.Vaccines (Basel). 2013 Dec 1;1(4):444-62. doi: 10.3390/vaccines1040444. Vaccines (Basel). 2013. PMID: 24967094 Free PMC article.
-
Reduced tumorigenesis of EG7 after interleukin-10 gene transfer and enhanced efficacy in combination with intratumorally injection of adenovirus-mediated lymphotactin and the underlying mechanism.Cancer Immunol Immunother. 2011 Apr;60(4):559-73. doi: 10.1007/s00262-010-0955-5. Epub 2011 Jan 15. Cancer Immunol Immunother. 2011. PMID: 21240488 Free PMC article.
-
Dendritic Cells and Cancer: From Biology to Therapeutic Intervention.Cancers (Basel). 2019 Apr 11;11(4):521. doi: 10.3390/cancers11040521. Cancers (Basel). 2019. PMID: 30979057 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials